Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Continuous Glucose Monitoring System Offers Improved Accuracy

By LabMedica International staff writers
Posted on 23 Aug 2018
Frequent use of continuous glucose monitoring systems is associated with improved glycemic outcomes in persons with diabetes, but the need for calibrations and sensor insertions are often barriers to adoption.

A newly improved, factory-calibrated, continuous glucose monitoring (CGM) system provided accurate glucose readings for 10 days (240 hours) and removed a number of clinical barriers to widespread CGM use, such as acetaminophen interference and complicated adjustments.

Scientists at the University of Colorado Denver (Aurora, CO, USA) and their colleague tested the accuracy of the improved G6 CGM system, which includes a thinner and smaller transmitter, predictive low glucose alert, sensor membrane to block acetaminophen, and 10-day sensor wear. More...
The current study enrolled 151 youth (age 6 to 17) and 139 adults with type 1 and 2 diabetes from 11 sites within the USA.

Youth participants returned for one clinic session of six hours, and adults for three clinic sessions of up to three hours, during which CGM readings were compared with venous glucose concentrations in a laboratory setting. Glucose levels were manipulated for the 202 participants over the age of 13 to determine that the G6 CGM system, was adequately covering the entire reportable 40-400 mg/dL range. Performance evaluation included the proportion of CGM values that were within ±20% of reference glucose values greater than 100 mg/dL or within ±20 mg/dL of reference glucose values ≤100 mg/dL (%20/20), the analogous (%15/15), and the mean absolute relative difference (MARD, expressed as a percentage) between temporally matched CGM and reference values.

The data from 262 study participants (21,569 matched CGM reference pairs) were analyzed. The overall %15/15, %20/20, and MARD were 82.4%, 92.3%, and 10.0%, respectively. Matched pairs from 134 adults and 128 youth of ages 6–17 years were similar with respect to %20/20 (92.4% and 91.9%) and MARD (9.9% and 10.1%). Overall %20/20 values on days 1 and 10 of sensor wear were 88.6% and 90.6%, respectively. The system's “Urgent Low Soon” (predictive of hypoglycemia within 20 minutes) hypoglycemia alert was correctly provided 84% of the time within 30 minutes before impending biochemical hypoglycemia (<70 mg/dL). The 10-day sensor survival rate was 87%.

The authors concluded that the new factory-calibrated G6 real-time CGM system provides accurate readings for 10 days and removes several clinical barriers to broader CGM adoption. The study was published online on June 1, 2018, in the journal Diabetes Technology & Therapeutics.

Related Links:
University of Colorado Denver


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.